Are closed systems the future of CGT sterility testing?
Researchers have identified, for the first time, a sensitive, low-risk, closed-system for the detection of fungal contaminants in cell and gene therapy (CGT) products.
List view / Grid view
Researchers have identified, for the first time, a sensitive, low-risk, closed-system for the detection of fungal contaminants in cell and gene therapy (CGT) products.
Driven by oncology drug demand, the highly potent active pharmaceutical ingredients (HPAPIs) market is anticipated to grow by $7bn in three years.
Phase I study shows that mRNA-based individualised neoantigen specific immunotherapy (iNeST) vaccines can be used to stimulate T cells to recognise neoantigens in pancreatic cancer patients.
A data collection study provides a product quality dataset that could form the basis of advanced analytical models to predict final product quality.
Here, EPR summarises a recent review, outlining the critical considerations when setting occupational exposure limits (OELs), with a focus on HPAPIs.
Ambitions to reach greater numbers of patients with unmet need have fuelled some benevolent plans from bio/pharmaceutical companies ViiV Healthcare and Sandoz.
Research reveals how combining sample sectioning with Raman imaging enables the three-dimensional (3D) imaging of an oral solid dosage form matrix.
Recent ABPI figures show Northern Ireland’s life sciences sector supports 19,500 jobs directly, 15,000 jobs indirectly and is worth £2.4 billion.
With recalls on metformin products containing nitrosamines ongoing, a study suggests >80 percent of metformin APIs and final drug products are within safe limits.
Following the recent spate of monkeypox cases across Europe and North America, The Lancet has published insights from a study of seven UK monkeypox cases between 2018 and 2021.
GSK will pay up to $3.3 billion to acquire Affinivax, gaining access to its Multiple Antigen Presenting System (MAPS) technology and pneumococcal vaccine candidates.
Eli Lilly and Company announces plans to establish two new manufacturing facilities in Indiana USA worth $2.1 billion.
Among several alternative methods, X-ray irradiation is being considered as a potential pharmaceutical sterilisation process. Here, EPR summarises the salient points of a paper exploring why.
Setting a new philanthropic benchmark, Pfizer is launching Accord for a Healthier World - an initiative aimed at closing the gap on inequalities with low-income countries.
Israel Biotech Fund (IBF) and Lonza announce agreement to accelerate the development and manufacture of Israeli biologics and small molecules.